ALLK (Allakos) 1-Year Share Buyback Ratio : -2.20% (As of Dec. 2024 )

View and export this data going back to 2018. Start your Free Trial

What is Allakos 1-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Allakos's current 1-Year Share Buyback Ratio was -2.20%.

ALLK's 1-Year Share Buyback Ratio is ranked better than
72.8% of 1202 companies
in the Biotechnology industry
Industry Median: -13.8 vs ALLK: -2.20

Competitive Comparison of Allakos's 1-Year Share Buyback Ratio

For the Biotechnology subindustry, Allakos's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allakos's 1-Year Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allakos's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Allakos's 1-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Allakos 1-Year Share Buyback Ratio Calculation

Allakos's 1-Year Share Buyback Ratio for the quarter that ended in Dec. 2024 is calculated as

1-Year Share Buyback Ratio	=	(Shares Outstanding (EOP) (Dec. 2023 )	-	Shares Outstanding (EOP) (Dec. 2024 ))	/	Shares Outstanding (EOP) (Dec. 2023 )
	=	(87.750	-	89.649)	/	87.750
	=	-2.2%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allakos (NAS:ALLK) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Allakos 1-Year Share Buyback Ratio Related Terms

Allakos Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allakos Inc (NAS:ALLK) » Definitions » 1-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

37Z:Germany

Address

825 Industrial Road, Suite 500, San Carlos, CA, USA, 94070

Website

https://www.allakos.com

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.

Executives

Harlan Baird Radford	officer: Chief Financial Officer	C/O EBAY INC., 2145 HAMILTON AVENUE, SAN JOSE CA 95125
Graham Neil Murray Hamilton	director	33 MT. GREEN RD, CROTON ON HUDSON, NEW YORK NY 10520
Everett Rand Sutherland	director	29 HARTWELL AVENUE, LEXINGTON MA 02421
Dolca Thomas	director	C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Paul Edward Walker	director	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Daniel Janney	director	PO BOX 7414, JACKSON WY 83002
Amy L Ladd	director	INTUITIVE SURGICAL, INC, 1020 KIFER RD, SUNNYVALE CA 94086
Craig A. Paterson	officer: Chief Medical Officer	ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070
Margaret Nell Fitzgerald	officer: General Counsel and Secretary	ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070
Steven P James	director	C/O OCERA THERAPUETICS, 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Adam Tomasi	officer: COO, CFO and Secretary	ZS PHARMA, INC., 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Robert Alexander	director, officer: President and CEO	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Rasmussen Henrik S Md	officer: Chief Medical Officer	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
John P Mckearn	director, 10 percent owner	5820 NANCY DRIVE, SAN DIEGO CA 92121
Peter A Hudson	10 percent owner	701 COOL SPRINGS BOULEVARD, FRANKLIN TN 37067